Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02967731 | 480 Biomedical Sinus Drug Depot | PHASE1 | COMPLETED | 20 | — | — | Jun 6, 2017 | May 18, 2018 | Aug 25, 2021 | 4 | Australia, New Zealand |
| Arm | Type | Description |
|---|---|---|
| 480 Mometasone Furoate Sinus Drug Depot | EXPERIMENTAL | 480 Mometasone Furoate Sinus Drug Depot |
| Name | Type | Description |
|---|---|---|
| 480 Mometasone Furoate Sinus Drug Depot | DRUG | Management of Chronic Sinusitis |
Inclusion Criteria: * Diagnosis of CS. * Female study subjects of child-bearing potential must have a negative pregnancy test and must agree to not become pregnant during the course of the study. * The study subject has been informed of the nature of the study, agrees to its provisions and has prov...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Itepekimab, Mometasone furoate, lunsekimig |
| AstraZeneca PLC | AZN | 4 | PHASE3 | Tezepelumab |
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |